Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Liabilities and Shareholders Equity (2016 - 2025)

Standard Biotools (LAB) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $567.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 7.28% to $567.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, down 19.29% year-over-year, with the annual reading at $567.8 million for FY2025, 7.28% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $567.8 million at Standard Biotools, up from $539.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $777.7 million in Q1 2024, with the low at $271.9 million in Q1 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $454.2 million, with a median of $402.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 109.24% in 2024, then dropped 25.47% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $275.2 million in 2021, then soared by 41.82% to $390.3 million in 2022, then decreased by 17.23% to $323.1 million in 2023, then soared by 89.54% to $612.3 million in 2024, then dropped by 7.28% to $567.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $567.8 million, $539.6 million, and $557.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.